Merck & Co., Inc. (MRK): Total Assets
$136.87B
As of 2025-12-31
$129.80B
As of 2026-06-30
+7.8%
3-year compound annual growth
+8.4%
5-year compound annual growth
+3.0%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $136.87B | +16.9% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $117.11B | +9.8% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $106.67B | -2.3% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $109.16B | +3.3% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $105.69B | +15.4% | 2023-02-24, Balance as of period end |
| 2020-12-31 | $91.59B | +8.5% | 2022-02-25, Balance as of period end |
| 2019-12-31 | $84.40B | +2.1% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $82.64B | -6.0% | 2020-02-26, Balance as of period end |
| 2017-12-31 | $87.87B | -7.9% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $95.38B | -6.2% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $101.68B | +3.6% | 2017-02-28, Balance as of period end |
| 2014-12-31 | $98.17B | -7.1% | 2016-02-26, Balance as of period end |
| 2013-12-31 | $105.64B | -0.5% | 2015-02-27, Balance as of period end |
| 2012-12-31 | $106.13B | +1.0% | 2014-02-27, Balance as of period end |
| 2011-12-31 | $105.13B | -0.6% | 2013-02-28, Balance as of period end |
| 2010-12-31 | $105.78B | -5.8% | 2012-02-28, Balance as of period end |
| 2009-12-31 | $112.31B | +138.0% | 2011-02-28, Balance as of period end |
| 2008-12-31 | $47.20B | n/a | 2010-03-01, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $133.96B | -0.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $40.75B | +3.6% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $40.56B | +7.4% |
Compare MRK, LLY, PFE, ABBV side by side · Screen every company in Pharmaceutical Preparations ↗